Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- (-) Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- (-) Clinical Pathways
- Decision Frameworks
- Elements of Value
- (-) Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- (-) Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Display Only
Showing 53 Results
Characterizing health plan evidence review practices: how often, how different, and how comprehensive?
All health care decisions should be evidence-based. Until now, it has been relatively unclear what goes into health plan evidence reviews. How frequently do health plans update their specialty drug…
NPC Submits Comments on Medicare Physician Fee Schedule Proposed Rule
NPC submitted comments on the Medicare Program’s CY 2022 Physician Fee Schedule proposed rule recommending opportunities to enhance understanding of patient-reported outcomes and address barriers to…
NPC in Health Affairs: Payment Innovation Not Keeping Up
In a Health Affairs Blog article, NPC and MIT researchers outline how a new rule from CMS may fall short of what is needed to improve patient access to durable cell and gene therapies that target…
Webcast: Priorities for Patient-Centered Care in Oncology
On a recent webcast, NPC Vice President of Health Services Research Kimberly Westrich discusses the importance of patient-centered care and the benefits and opportunities of incorporating…
NPC Shared Decision-Making and Value-Based Care Research Featured at PQA Annual Meeting
Research conducted by NPC and Discern Health found that shared decision-making and patient decision aid interventions do not always lead to reduced health care costs or utilization.
Patient Voices in Value-Based Cancer Care: Priorities for the Biden Administration
The key to elevating patient voices is using the right tools when developing a value-based payment model: patient-reported measures (PRMs), tools that capture patients’ voices related to their care…
Chairman’s Blog: Let Data and Research Guide the Pricing and Access Policy Debate
NPC Board Chair and BMS SVP Michael Ryan reflects on the biopharmaceutical industry's role in solving global health challenges and how to address misunderstandings about what it takes to bring…
Social Determinants Interventions: Good Policy Solutions Require Good Data
In his AJMC editorial, NPC Interim President and CEO Dr. Robert Dubois says we need to address social determinants of health and improve patients’ lives through approaches based on strong data.
Improving Patient-reported Measures in Oncology: A Call to Action
This study explores the current landscape of oncology patient-reported measures (PRMs), which are tools that capture patients’ voices related to their care experience and outcomes.
Are Value-based Arrangements the Answer We’ve Been Waiting for?
This NPC study explored the use of value-based arrangements as a mechanism for cost containment in the United States, noting the strengths and limitations of these tools.
AMCP Partnership Forum: Optimizing Prior Authorization for Appropriate Medication Selection
Stakeholders focused on the challenges of current prior authorization and step therapy programs, approaches to improve these processes for patient care, and reviewed current legislative activities…
Little Consistency in Evidence Cited by Commercial Health Plans for Specialty Drug Coverage
Evidence cited by payers in coverage decisions for specialty medicines varies significantly, with health plans only citing the same study in 15% of health plan coverage policies for a given drug and…
NPC Research Featured in Two Panels on Patient-Reported Measures in Oncology
A white paper by the National Pharmaceutical Council and Discern Health, Improving Patient-reported Measures in Oncology, was highlighted during two recent panels discussing recommendations for…
Key Takeaways From an ISPOR Panel on Creative Financing Proposals
An expert panel was convened at the ISPOR 2019 annual meeting to discuss the need for novel payment approaches to address the challenges that accompany transformative therapies.
NPC in Specialty Pharmacy Times: Creative Financing for Innovative, Curative Therapies
States are getting creative about how they can meet the health care needs of their citizens, especially when it comes to curative treatments for conditions with a high rate of prevalence. More…
U.S. Care Pathways: Continued Focus on Oncology and Outstanding Challenges
A peer-reviewed study assessed changes in development, implementation, and evaluation of care pathways, and reviewed the latest evidence on integration of pathways with value-based care initiatives…
Symposium: Able to Cure, Able to Pay — Closing the Widening Gap
In Louisiana, significant prevalence of hepatitis C cases and high treatment costs has led the state to turn to an innovative idea – using a Netflix-style subscription model to pay for curative…
Loud and Clear: Key Takeaways from a Webinar on “Amplifying the Patient Voice” in Quality Measurement
In a Feb. 28 webinar from NPC and Discern Health, a group of diverse speakers discussed policy solutions for improving patient-reported measures in oncology value-based programs, along with a white…
Improving Patient-reported Measures in Oncology
This is a landscape analysis of available patient-reported measures and patient-reported performance measures in oncology and offers recommendations for filling gaps in measures and removing barriers…